Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lipoprostaglandin E1
- Development stage
- Phase 3
- Lead developer
- Mitsubishi Tanabe Pharma
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Epidural
01
Overview
Lipoprostaglandin E1 is a liposome-encapsulated form of prostaglandin E1 (PGE1). It functions as a potent vasodilator with antiplatelet, anti-inflammatory, and anti-thrombotic properties. The liposomal formulation improves the drug's pharmacokinetics and therapeutic index compared to conventional PGE1, allowing for efficacy at lower doses with fewer adverse effects. It efficiently accumulates in vascular lesions of nervous tissue and has been shown to prevent apoptotic cell death.
- Brand names
- EglandinLiprostinTLC C-53
- Other names
- Lipo-PGE1Lipo-PGE-1Lipo-PGE 1Liposomal prostaglandin E1
02
Targets
GP1BA (Platelet glycoprotein ib alpha chain)PTGER2 (Prostaglandin E2 receptor EP2)PTGER4 (Prostaglandin E2 receptor EP4 subtype)
Beyond the preview
Go deeper on lipoprostaglandin E1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lipoprostaglandin E1.